The mechanism of the coagulation of blood by staphylocoagulase and the relation of this process to physiological clotting present many unsolved problems. Evidence has been advanced for the concept that coagulase reacts with a plasma component (coagulase reacting factor CRF) which is distinct from prothrombin.5'4'1S1 The formation of an intermediate complex has been inferred from the shortening of the clotting time when some preparations of coagulase and plasma are incubated before the addition of fibrinogen.",6 A simplified representation of the reaction may thus be assumed to proceed along these lines:
Coagulase plus CRF = intermediate complex Intermediate complex plus fibrinogen = fibrin The evidence for the differentiation of CRF from prothrombin has been presented elsewhere."' That this concept has not been accepted without reservations is evident from the recent studies of Duthie and Lorenz,3 " who are not entirely convinced that prothrombin and CRF are separate entities and reconsider the possibility that CRF and prothrombin may be identical, or that CRF may be a modification of prothrombin. With regard to the formation of the "intermediate complex," while a shortening of the coagulation time when coagulase and plasma are incubated has been frequently noted, incubation of some preparations of plasma and coagulase, in past (unpublished) studies, failed to produce any significant acceleration of clotting.
These problems of coagulase clotting have prompted the present study of the action of trypsin and its inhibitor on this system. The acceleration of physiological clotting by trypsin has been recognized for many years,2"' and more recently, the inhibitory capacities of trypsin inhibitors, such as the soybean trypsin inhibitor of Kunitz have been established.1 ' 8', The isolation of these agents in crystalline form'" has helped to resolve earlier conflicts' which stemmed from the use of impure reagents in improper amounts. The primary purpose of the present study, therefore, was to investigate the action of the trypsin and its inhibitor on coagulase clotting, with the object of possibly disclosing some differences from, or similarities to, the mode of action of these agents on physiological clotting. The use of the enzyme inhibitor was further suggested as a means of investigating the mechanism of CRF loss when blood coagulates. In a recent study,'9 this CRF consumption has been shown to depend on prothrombin conversion. Since this reaction constitutes a possible link between the coagulase and the physiological clotting systems, and since there is evidence that proteolysis occurs during prothrombin conversion, the effect of the tryptic inhibitor on this reaction seemed worthy of study.
MATERIALS AND METHODS
Coagulase-a partially purified cell-free product derived from Staphylococcus aureus $104'1 was used throughout.
Plasma-dilutions of citrated human blood bank discards were used as the source of CRF.
Fibrinogen 
RESULTS
The effect of crystalline trypsin on the coagulase clotting of plasma. Previous studies have demonstrated that crude and crystalline trypsin will inactivate coagulase."'2X For the present purposes, therefore, minute amounts of trypsin were selected which produced no evident fall in coagulase titer during the period of observation. Both the plasma and the trypsin dilutions were made in citrated saline. Trypsin at the concentrations indicated in Table 1 , the plasma dilution, and coagulase were mixed in equal volumes, and 0.2 ml. samples were withdrawn and reacted with 0.2 ml. of fibrinogen at the stated times. The potentiating effect of 1 microgram and of 0.5 micrograms of trypsin was readily apparent, while 0.1 micrograms/ml. of trypsin was without effect. Even this minute amount, however, accelerated physiological clotting (Table 2) .
In subsequent experiments, heparin in excess was also added to the plasma before reacting with trypsin and coagulase. The same acceleration of clotting in the test system was noted, while no clotting was noted in the trypsin-plasma controls at any of the levels observed. tions, such as 6,000-12,000 micrograms/ml. produced some prolongation of the clotting time. Attention was, therefore, directed towards evaluating the possibility that SBTI may interfere in the coagulase-CRF reaction. Accordingly, equal volumes of various concentrations of SBTI, of suitable plasma dilutions, and of coagulase were mixed, and 0.2 ml. of the incubation mixture added to 0.2 ml. of fibrinogen at various time intervals. It will be noted (Table 3 ) that the coagulase clotting system proved highly refractory to the action of SBTI. Only at excessively high levels is there a delay in the initial clotting time-comparable to the effect on preincubating the inhibitor and coagulase-while the shortening of the coagulation time upon incubation of coagulase and CRF is not blocked even at these excessive levels of inhibitor.
In subsequent experiments, modifications of the above procedure were explored in seeking conditions which might reveal a significant effect. Dilutions of plasma, from 1: 10 to 1: 1000 were tested against a range of coagulase dilutions, as well as plasma samples which had been subjected to five successive Seitz filtrations to remove prothrombin activity. Neither was any significant effect on the initial clotting time noted except at the very high levels of inhibitor, nor was the shortening of the clotting time follow- (Table 4 ).
The effect of SBTI on the CRF loss incurred during prothrombin conversion. It has been shown that the conversion of plasma to serum results in a loss of CRF.4"''9 and that conditions which favor the most effective prothrombin conversion bring about maximal CRF loss. Since SBTI interference with the physiological coagulation presumably involves prothrombin conversion, it seemed indicated to determine whether interference with proteolysis would spare CRF. In the experiment summarized in Table 5 , plasma was converted by calcium and thromboplastin (rabbit brain), and various concentrations of SBTI were incorporated in the conversion mixture. After coagulation occurred, the clots were shaken loose, and the samples incubated at 370 C. for two hours to allow antithrombin to form. The sera were then diluted, and aliquots titrated for CRF by the addition of coagulase and fibrinogen. It will be noted that as little as 0.4 micrograms/ml.
of SBTI (#5) partially blocked CRF loss, while the effect of the further dilutions of the SBTI approached the conversion control (#8). On the other hand, even at the maximal concentration of SBTI tested, 4000 micrograms/ml. (#1), the residual CRF titer did not attain the level of the sample in which no prothrombin conversion occurred (#9). Subsequent experiments were confirmatory of these findings. Finally, the removal of directly demonstrable prothrombin activity by five successive Seitz filtrations abolished CRF loss regardless of the addition of calcium, thromboplastin, or SBTI.
DISCUSSION
Many observations have favored the distinctiveness of coagulase clotting from the physiological process. Among these may be mentioned the failure of citrate, oxalate, and of heparin to interfere with coagulase activity. Highly purified bovine prothrombin of Seegers is all but completely devoid of CRF even when reacted with coagulase preparations of high potency and purity."8 The dissociation of prothrombin activity from CRF by serial Seitz filtration also supports this concept."
That many of the arguments admit of alternative interpretations cannot be denied. Thus, the activation of prothrombin by systems other than calcium and "thromboplastin" is receiving wide recognition. It is known that Seitz filtration does not eliminate all prothrombin activity,"" and that, indeed, some additional activity may be regenerated by appropriate chemical procedures from what appear to be prothrombin-free filtrates. Duthie and Lorenz' suggest that it may be conceivable that repeated Seitz filtration may actually not remove prothrombin, but that this procedure so alters it that, while it can no longer be converted to thrombin, it still retains its ability to react with coagulase. It is of interest in this regard to note that CRF properties are modified when separation from prothrombin is achieved by serial Seitz filtration,= suggesting, though not proving, a possible close relationship between the two agents in the native state. Duthie and Lorenz' also interpret parallel CRF and prothrombin loss consequent on prothrombin conversion, as well as the similar effects of dicoumarol administration on prothrombin and CRF, as pointing in the same direction.
The present writer continues to favor the view that prothrombin and CRF are not identical, and that the two clotting mechanisms are distinct.
Final solution of the problem awaits adequate purification of CRF. Attempts in this direction have met with only limited success. Although purification of the order of one hundred and twenty-five-fold has been attained, the products proved highly labile and were not free of slight traces of prothrombin activity.= The studies here reported have afforded a further basis for comparison of the two clotting systems. Both responded to minute concentrations of added trypsin. The coagulase clotting system, however, proved all but completely refractory when tested against excessively high levels of two lots of inhibitor. There was no evidence of any effect on the initial clotting time except at very high levels of SBTI, and the formation of the "interinediate complex" was not blocked at any level of inhibitor tested. The same lots of SBTI, in minute amounts, proved effective in delaying the clotting of citrated plasma by recalcification. If the activation of prothrombin involves proteolytic enzyme systems vulnerable to SBTI, then the coagulase reaction either involves proteolytic enzyme systems of different specificities or proceeds along diverse pathways altogether.
The acceleration of the clotting of plasma by the addition. of minute quantities of trypsin to coagulase suggests the need for caution in the interpretation of the formation of an "intermediate complex" when coagulase and CRF are incubated. The presence of proteolytic enzymes in either crude coagulase' or in plasma may contribute to such acceleration. However, in the present studies, the order of acceleration resulting from the incubation of partially purified coagulase and diluted plasma was far slighter than the shortening of the clotting time occurring when trypsin was added. It is noteworthy, too, that while an excess of SBTI abolishes the superimposed accelerating effect of trypsin, the base-line acceleration is not disturbed. The suggestion may be entertained that some of the more striking accelerations""' reported in the literature when coagulase and CRF are incubated may represent a summation of a true "intermediate complex" and the activity of contaminating proteolytic enzymes.
Milstone'5 has presented evidence that the thrombokinase, the activator of prothrombin, is an enzyme, possibly proteolytic. The sparing effect of minute quantities of SBTI on CRF loss after prothrombin conversionquite within the range of trypsin and trypsin inhibitor activity on physiological clotting-makes it seem acceptable that proteolysis occurring during prothrombin conversion is the mechanism underlying this CRF loss.
SUMMARY
Crystalline trypsin at concentrations of the order of 0.5 to 1 microgram/ml., accelerates the clotting of plasma by coagulase.
Contrary to its effect on physiological clotting, crystalline soybean trypsin inhibitor (SBTI) fails to influence the coagulase clotting process, with the exception that a slight prolongation of initial clotting time takes place at high levels of inhibitor. SBTI effectively, though not completely, blocks CRF loss incurred during prothrombin conversion.
